Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04754191 · ClinicalTrials.gov registry record · Phase 2

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by University of Utah.

Active
Registry status
Phase 2
Development phase
34
Enrollment target
1
Study location

NCT04754191: Active Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by University of Utah.

NCT04754191 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 34 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04754191, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer. The trial will open to enrollment in Cohort A, enfortumab monotherapy. Additional cohorts may be added as new drug combinations are identified.

Primary Outcome

To assess the anti-tumor action of the study therapy in subjects with metastatic castrate-resistant prostate cancer, as represented by the proportion of subjects achieving one of the following outcomes: Objective response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; Confirmed conversion of circulating tumor cell count (CTC) to \<5/7.5 mL blood; Prostate Specific Antigen (PSA) decline ≥ 50% from baseline; or Stable disease ≥ 6 months per Prostate Cancer Working Group 3 (PCWG3)-m

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Enfortumab vedotin

Study Locations (1)

Utah

  • Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2022-06-05
Est. Completion 2027-01
Phase Phase 2
University of Utah

818 total trials

What the registry record for NCT04754191 still lists

NCT04754191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Enfortumab vedotin is the first listed.

NCT04754191 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT04754191 about?

NCT04754191 is a clinical study titled "Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer". This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer. The trial will open to enrollment in Cohort A, enfortumab monotherapy. Additional co...

What is the current status of trial NCT04754191?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2022-06-05. Estimated completion is 2027-01.

What conditions does trial NCT04754191 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT04754191?

The interventions under investigation include: Enfortumab vedotin (DRUG).

Who is sponsoring clinical trial NCT04754191?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04754191 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04754191's enrollment target sits among peer trials

34 55th of 69 higher than 15 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04754191, the US trial registry maintained by the National Library of Medicine. NCT04754191 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.